<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501603</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-0244</org_study_id>
    <nct_id>NCT02501603</nct_id>
  </id_info>
  <brief_title>Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer</brief_title>
  <official_title>An Open-label, Multicenter Phase II Study of Afatinib Plus Weekly Taxol as Second Line Treatment for Advanced/Recurrent Gastric and Gastroesophageal Junction Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the gastric cancer, paclitaxel is recommended as salvage standard treatment. Afatinib is&#xD;
      a novel, potent, small ErbB family blocker that covalently binds and irreversibly blocks&#xD;
      signaling through activated EGFR, HER2 and ErbB4 receptors, as well as the&#xD;
      transphosphorylation of ErbB3. The investigators suggest a randomized phase II trial of&#xD;
      afatinib plus weekly taxol(paclitaxel) for previously treated EGFR positive gastric cancer&#xD;
      patients. The aim of current trial is to evaluate the antitumor efficacy of afatinib for&#xD;
      target enriched patients in gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare progression free survival as measured by RECIST 1.1</measure>
    <time_frame>Every 6 weeks until progression, an expected average of 10 months</time_frame>
    <description>To identify antitumor activity of afatinib plus weekly taxol(paclitaxel) and explore predictive biomarker</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>antitumor efficacy as measured by RECIST 1.1</measure>
    <time_frame>every 6 weeks until progression, an expected average of 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety as measured by CTCAE</measure>
    <time_frame>every 3 weeks until progression, an expected average of 10 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Cancer</condition>
  <arm_group>
    <arm_group_label>afatinib plus paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>afatinib plus paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>afatinib</intervention_name>
    <description>Afatinib 40mg daily oral administration</description>
    <arm_group_label>afatinib plus paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel 80mg/m2 IV weekly (day 1,8,15)</description>
    <arm_group_label>afatinib plus paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed locally advanced or metastatic gastric&#xD;
             cancer and gastroesophageal junction cancer&#xD;
&#xD;
          2. EGFR 2+ or 3+ expression (immunohistochemistry)&#xD;
&#xD;
          3. ECOG performance status of 0 to 1&#xD;
&#xD;
          4. Male or female; ≥ 19 years of age&#xD;
&#xD;
          5. Documented disease progression after one prior therapy, in locally advanced or&#xD;
             metastatic setting&#xD;
&#xD;
          6. patients received last adjuvant chemotherapy less than six months can be enrolled into&#xD;
             this study&#xD;
&#xD;
          7. Her2 positive patients must be progressed after prior trastuzumab based chemotherapy&#xD;
&#xD;
          8. Subjects with measurable lesion (using RECIST 1.1 criteria)&#xD;
&#xD;
          9. Subjects who meet the following criteria:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1000 /µL (*ANC = Neutrophil segs ＋ Neutrophil&#xD;
                  bands)&#xD;
&#xD;
               -  Platelet count ≥ 80,000/ µL&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 x upper limit of normal (ULN) or Creatinine clearance ≥50&#xD;
                  mL/min using Cockcroft, Gault method&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) : 3 x upper limit of normal (ULN) (If there is Liver&#xD;
                  Metastasis : 5 x upper limit of normal (ULN))&#xD;
&#xD;
               -  Total bilirubin : 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
         10. Provision of written informed consent prior to any study procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer&#xD;
             therapy.&#xD;
&#xD;
          2. Any previous chemotherapy or immunotherapy within 2 weeks&#xD;
&#xD;
          3. Any major operation or irradiation within 4 weeks of baseline disease assessment&#xD;
&#xD;
          4. Two or more previous systemic cytotoxic chemotherapy (adjuvant chemotherapy is not&#xD;
             counted)&#xD;
&#xD;
          5. Any clinically significant gastrointestinal abnormalities which may impair intake or&#xD;
             absorption of the study drug&#xD;
&#xD;
          6. Previously taxol(paclitaxel)-exposed patients&#xD;
&#xD;
          7. Subjects with symptomatic central nervous system (CNS) metastases who are&#xD;
             neurologically unstable or have required increasing doses of steroids within the 2&#xD;
             weeks prior to study entry to manage CNS symptoms&#xD;
&#xD;
          8. Other co-existing malignancies or malignancies diagnosed within the last 3 years with&#xD;
             the exception of basal cell carcinoma, thyroid cancer or cervical cancer in situ.&#xD;
&#xD;
          9. Subjects with an uncontrolled major cardiovascular disease (including AMI within 12&#xD;
             months, unstable angina within 6 months, over NYHA class III congestive heart failure,&#xD;
             congenital long QT syndrome, 2° or more AV Block and uncontrolled hypertension)&#xD;
&#xD;
         10. Pregnant or lactating female&#xD;
&#xD;
         11. Patients with contraindicated medication&#xD;
&#xD;
         12. History of interstitial lung disease (ILD) or presence of ILD on chest X-ray&#xD;
&#xD;
         13. Evidence of any other significant clinical disorder or laboratory finding that makes&#xD;
             it undesirable for the patient to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun Young Rha</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital, Yonsei University Health System, Yonsei Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System, Yonsei Cancer Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Sun Young Rha</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

